ライフサイエンスコーパス: GLP-2

1 ivation control the elimination of bioactive GLP-2.

2 d in TPN-fed pigs acutely (4 h) infused with GLP-2.

3 , truncated GLP-1, and N-terminally extended GLP-2.

4 ion (TPN alone), +/- SEN (days 4-6), and +/- GLP-2 (100 mug . kg body wt(-1) . d(-1)).

5 atments and TPN alone (SEN: 15-59% increase; GLP-2: 14-84% increase; and SEN + GLP-2: 63-160% increas

6 /- 10 pmol/L; GLP-2: 59 +/- 31 pmol/L; SEN + GLP-2: 246 +/- 40 pmol/L) and correlated with mucosal gr

7 h saline (control) for 4 hours and then with GLP-2 (500 pmol x kg(-1) x hour(-1), GLP-2) for 4 hours.

8 one: 25 +/- 9 pmol/L; SEN: 29 +/- 10 pmol/L; GLP-2: 59 +/- 31 pmol/L; SEN + GLP-2: 246 +/- 40 pmol/L)

9 increase; GLP-2: 14-84% increase; and SEN + GLP-2: 63-160% increase).

10 a-helices within glucagon and GLP-1, but not GLP-2, act as sorting signals by efficiently directing a

11 GLP-2 acutely increased PDV glucose uptake (+90%) and ne

12 GLP-2 acutely increased portal-drained visceral (PDV) bl

13 We conclude that in TPN-fed neonatal pigs, GLP-2 acutely stimulates intestinal blood flow and gluco

14 sits 4 weeks apart, to assess the effects of GLP-2 administration on triglyceride-rich lipoprotein (T

15 GLP-2 administration resulted in a rapid (within 30 minu

16 GLP-2 also enhances gut barrier function and induces pro

17 GLP-2 also increased intestinal constitutive nitric oxid

18 pharmacokinetic characteristics, a series of GLP-2 analogues containing Gly substitution at position

19 resence of SCFA sensing in the duodenum with GLP-2 and 5-HT signals further supports the hypothesis t

20 The actions of growth factors such as GLP-2 and EGF are now known to be complex, demonstrating

21 consecutive intravenous infusions of saline, GLP-2, and GLP-2 plus N(G)-Nitro-L-arginine methyl ester

22 d endocrine hormones, especially insulin and GLP-2, and stress.

23 GLP-1 and GLP-2 are both cleaved by dipeptidyl peptidase-4 (DPP-4)

24 mine whether the intestinotrophic effects of GLP-2 are mediated by acute up-regulation of intestinal

25 The actions of GLP-2 are transduced via a single G protein-coupled rece

26 The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide an

27 In the validation study, administration of GLP-2 at 7 hours after the meal, in the absence of addit

28 GLP-2 circulates at low basal levels in the fasting peri

29 ndings from both preclinical studies and the GLP-2 clinical development program for short bowel syndr

30 e intestinotrophic response to a low dose of GLP-2 coinfused with PN in a rat model of SBS (60% jejun

31 GLP-1 and GLP-2 coinfusion resulted in net increased lipid absorpt

32 peak plasma cholecystokinin, PYY, GLP-1, and GLP-2 concentrations being attained after jejunal feedin

33 tide 1 (GLP-1), and glucagon-like peptide 2 (GLP-2) concentrations was greater after jejunal feeding

34 In contrast, the gut-derived peptide GLP-2, cosecreted from intestinal L cells with GLP-1, ha

35 prolonged (120-min) coinfusion of GLP-1 and GLP-2 decreased postprandial lipemia.

36 s showing no effect and others documenting a GLP-2-dependent delay in gastric emptying.

37 line in circulating glucagon-like peptide 2 (GLP-2) during TPN.

38 The gut hormone glucagon-like peptide-2 (GLP-2) facilitates intestinal absorption of lipids, but

39 en with GLP-2 (500 pmol x kg(-1) x hour(-1), GLP-2) for 4 hours.

40 functional connection to vascular action of GLP-2 in the gut.

41 nical role of glutamine, growth hormone, and GLP-2 in the treatment of short-bowel syndrome.

42 GLP-2 increased PDV indispensable amino acid uptake by 2

43 GLP-2 increases mesenteric blood flow and activates proa

44 ction, with GLP-1 significantly reducing and GLP-2 increasing postprandial chylomicronemia.

45 Combination treatment with SEN and GLP-2 induced a synergistic response resulting in greate

46 SEN + GLP-2 induced dramatic mucosal growth and greater plasma

47 We conclude that the GLP-2-induced stimulation of blood flow is mediated by v

48 active GLP-2 were significantly greater with GLP-2 infusion (TPN alone: 25 +/- 9 pmol/L; SEN: 29 +/-

49 In neonatal pigs, GLP-2 infusion dose-dependently stimulated intestinal bl

50 Hence GLP-2 integrates nutrient-derived signals to optimize mu

51 greater plasma concentration of GLP-2 (SEN x GLP-2 interaction, P < 0.0001).

52 ion, food intake, and satiety signaling, and GLP-2 is implicated in regulating small-bowel growth.

53 c, dipolar alpha-helix, whereas the helix in GLP-2 is not dipolar.

54 Glucagon-like peptide-2 (GLP-2) is a 33-amino-acid proglucagon-derived peptide se

55 Glucagon-like peptide 2 (GLP-2) is a nutrient-dependent, proglucagon-derived gut

56 Glucagon-like peptide-2 (GLP-2) is a nutrient-responsive hormone that exerts dive

57 These findings suggest that GLP-2 may play an important physiological role in the re

58 Previous studies assessing the effect of GLP-2 on gastric emptying in humans have yielded inconsi

59 ning retinyl palmitate and were given either GLP-2 or placebo 7 hours later with measurement of TRL t

60 onse, including possible hypersensitivity to GLP-2 or reduced sensitivity to GLP-1.

61 GLP-2 plays a key role in the control of energy absorpti

62 Co-infusion of GLP-2 plus L-NAME did not increase either PDV blood flow

63 intravenous infusions of saline, GLP-2, and GLP-2 plus N(G)-Nitro-L-arginine methyl ester (L-NAME, 5

64 ) inhibition, at the same time as increasing GLP-2 portal blood concentrations.

65 e the intestinotrophic response to exogenous GLP-2, possibly by stimulating enterocyte proliferation

66 mal physiological conditions, the actions of GLP-2 predominate; however, when GLP-1 activity is susta

67 The discovery that GLP-2 promotes mucosal growth in the intestine is descri

68 In search of GLP-2 receptor agonists with better pharmacokinetic char

69 anced by DPPIV inhibition and inhibited by a GLP-2 receptor antagonist.

70 od flow and that nitric oxide is involved in GLP-2 receptor function.

71 ve FFA1 agonist increased DBS accompanied by GLP-2 release, enhanced by DPPIV inhibition and inhibite

72 O3(-) exchanger inhibition without affecting GLP-2 release, implicating acetate absorption in the par

73 nd presumably FFA3 by SCFA increased DBS via GLP-2 release, whereas FFA2 activation stimulated DBS vi

74 A short (30-min) intravenous infusion of GLP-2 resulted in a marked increase in postprandial apol

75 In vitro receptor potency at the human GLP-2, selectivity vs the human GLP-1 and GCG receptors,

76 l growth and greater plasma concentration of GLP-2 (SEN x GLP-2 interaction, P < 0.0001).

77 actions of glucagon-like peptide (GLP)-1 and GLP-2, the two major enteroendocrine L-cell peptides.

78 Administration of GLP-2 to men causes the release of chylomicrons that com

79 the apparent paradoxical roles of GLP-1 and GLP-2 under physiological conditions in the Syrian golde

80 Plasma concentrations of bioactive GLP-2 were significantly greater with GLP-2 infusion (TP